Tumor metastasis with a twist

	Tweet

In the early stages of human embryogenesis, a transcription factor called Twist1 plays a key regulatory role in how the embryo assumes form and function. Much later in life, however, researchers at the University of California, San Diego School of Medicine, say Twist1 can re-emerge, taking a darker and more deadly turn.

In a paper published in the March 15, 2011 issue of Cancer Cell, UCSD scientists led by Jing Yang, PhD, assistant professor of pharmacology and pediatrics, identify a unique function of Twist1 in later life: it promotes the formation of invadopodia in tumor cells, a vital step in the spread of such cells (metastasis) to surrounding tissues and other parts of the body.

Invadopodia (meaning “invasive feet") are tiny protrusions of tumor cells that extend into the extracellular matrix—the surrounding connective tissue and fibers that provide support. Invadopodia concentrate enzymes that degrade the matrix so that tumor cells can break away and metastasize. 

Previous studies have linked the expression of Twist1 to many aggressive, solid-tumor cancers, including melanomas, neuroblastomas, as well as breast and prostate cancer. The new research by Yang and colleagues describes in detail how Twist1 initiates the multi-step pathway resulting in invadopodia formation and matrix degradation. The research also reveals places in the process that may present potential targets for future anti-metastasis therapies.

After embryogenesis, Twist1 is normally suppressed. Cancer cells, however, reactivate the transcription factor, enabling Twist1 to initiate its complex pathway leading to metastasis. Drug designers, however, have yet to successfully devise a way to directly inhibit transcription factors like Twist1. The UCSD study points to other possibilities.

“We hope to inhibit downstream targets of Twist1 (such as platelet-derived growth factor receptors) to inhibit invadopodia formation and function,” Yang said. “Our study suggests that inhibition of invadopodia-mediated matrix degradation could be an effective way to suppress metastasis.”

If that happens, a cancer tumor becomes a stable, unmoving and easier target for other types of therapeutic treatments.

###

Co-authors of the paper include Mark A. Eckert and Andrew T. Chang, UCSD Molecular Pathology Graduate Program and Biomedical Science Graduate Program; Thinzar M. Lwin and Etienne Danis, UCSD Department of Pharmacology; and Jihoon Kim and Lucila Ohno-Machado, UCSD Division of Biomedical Informatics.

Research funding came, in part, from the National Institutes of Health, the Sydney Kimmel Foundation for Cancer Research, the California Breast Cancer Research Program and the Susan G. Komen Foundation.

###

Contact: Scott LaFee

619-543-6163
University of California - San Diego

RELATED STORIES:
Parents of kids with cancer face traumatic stress   Cancer gene therapy from camels   Cancer patients often forget details of doctor visit   Ludwig Fund gives $120 million for cancer research   Mechanism for invasion of tumorous cells discovered by Hebrew University researchers   Obesity-Related Cancer on the Rise   Keeping at-risk cells from developing cancer   Sleep apnea associated with higher mortality from cancer   U.S. cancer rates continue their decline: report   Young Volunteers Help Close Social Gap in Cancer Care   Immunotherapy for elderly cancer patients finds new promise in drug combination   Study Helps Explain Fundamental Process of Tumor Growth   9/11 firefighters have higher cancer risk: study   The solitary pulmonary nodule - malignant or benign?   Cancer rates in U.S. keep falling: American Cancer Society   Loud noise increases the risk of developing a non-cancerous tumor   High iron and cholesterol equals high cancer risk   Frequent Alcohol Consumption Increases Cancer Risk in Older Women   Researchers Examine Use of Toad Venom in Cancer Treatment   New cell findings have implications for cancer, immune disorders   Researchers unveil vital key to cancer   Cancer drug Gleevec may damage heart: study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]